Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case of a ...

EPS estimates but beats revenue expectations. Barclays downgrades stock, citing COVID demand decline and RSV uptake ...

Health care providers say that hesitation and outright resistance to vaccines have become disturbingly common even in ...

(Reuters) -Moderna said on Friday that the U.S. FDA paused a late-stage trial of its experimental norovirus vaccine after a case ... expected quarterly loss of $2.91 per share, compared to ...

Follow the latest COVID-19 Vaccine news stories and headlines. Get breaking news alerts when you download the ABC News App and subscribe to COVID-19 Vaccine notifications.

Moderna MRNA ... 2024 compared with $2.8 billion in the year-ago quarter. Per management, the decrease was primarily due to the earlier launch of the updated COVID-19 vaccine in the United States ...

Moderna reported a bigger-than-expected quarterly loss on Friday, hit by a charge related to its efforts to scale down ...

Moderna MRNA announced fourth-quarter 2024 results. Though earnings and sales beat estimates, both metrics declined ...

It marks another quarter of growing pains for the company, which is racing to launch new products and recover from the ...

Reports fourth quarter revenues of $1.0 billion, GAAP net loss of $(1.1) billion and GAAP EPS of $(2.91); loss ... including Moderna's next-generation COVID vaccine, RSV vaccine for high-risk ...

down from $2.8 billion a year ago but above analyst projections for $943 million, according to FactSet. Moderna said the earlier launch of its updated Spikevax vaccine shifted sales into the third ...